Alterations of ΔTA-p73 splice transcripts during melanoma development and progression

International Journal of Cancer

Volumn 108, Issue 1, 2004, Pages 162-166

  Tuve, Sebastian ^a   Wagner, Stephan N ^b   Schitrek, Birait ^c   Pützer, Brigitte M ^a,d  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^b Universitatsklinik fur Dermatologie   (Austria)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

E2F1; Melanoma; N terminally truncated p73 isoforms; Oncogene; TP73 gene

Indexed keywords

PROTEIN P53; PROTEIN P73; DNA BINDING PROTEIN; ISOPROTEIN; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WILD TYPE; GENETICS; METASTASIS; MUTATION; PIGMENTED NEVUS; TUMOR SUPPRESSOR GENE;

DNA-BINDING PROTEINS; GENES, TUMOR SUPPRESSOR; HUMANS; MELANOMA; MUTATION; NEVUS, PIGMENTED; NUCLEAR PROTEINS; PROTEIN ISOFORMS; TUMOR SUPPRESSOR PROTEINS;

EID: 0345256343     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11552     Document Type: Article

References (28)

1. Stiewe T, Putzer BM. Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ 2002;9:237-45.
2. Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D, Kaelin WG Jr. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol 1998;18:6316-24.
3. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000;404:99-103.
4. Tannapfel A, Wasner M, Krause K, Geissler F, Katalinic A, Hauss J, Mossner J, Engeland K, Wittekind C. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst 199;91:1154-8.
5. Zaika AI, Kovalev S, Marchenko ND, Moll UM, Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res 1999;59:3257-63.
6. Nozaki M, Tada M, Kashiwazaki H, Hamou MF, Diserens AC, Shinohe Y, Sawamura Y, Iwasaki Y, de Tribolet N, Hegi ME. p73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade. Brain Pathol 2001;11:296-305.
7. Novak U, Grob TJ, Baskaynak G, Peters UR, Aebi S, Zwahlen D, Tschan MP, Kreuzer KA, Leibundgut EO, Cajot JF, Tobler A, Fey MF. Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia. Ann Oncol 2001;12:981-6.
8. Stiewe T, Zimmermann S, Frilling A, Esche H, Putzer BM. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res 2002; 62:3598-602.
9. Stiewe T, Theseling CC, Putzer BM. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem 2002;277:14177-85.
10. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-19.
11. Ng SW, Yiu GK, Liu Y, Huang LW, Palnati M, Jun SH, Berkowitz RS, Mok SC. Analysis of p73 in human borderline and invasive ovarian tumor. Oncogene 2000;19:1885-90.
12. Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E, Spring K, Mould M, McGuckin MA, Lavin MF, Khanna KK. Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene 2001;20:514-22.
13. Stiewe T, Putzer BM. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 2000;26:464-9.
14. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH, Kaelin WG Jr. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 2000;407:645-8.
15. Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pirnia F, Hugli B, Graber HU, De Laurenzi V, Fey MF, Melino G, Tobler A. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 2001;8:1213-23.
16. Kartasheva NN, Contente A, Lenz-Stoppler C, Roth J, Dobbelstein M. p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop. Oncogene 2002;21:4715-27.
17. Lubbe J, Reichel M, Burg G, Kleihues P. Absence of p53 gene mutations in cutaneous melanoma. J Invest Dermatol 1994;102:819-21.
18. Kroiss MM, Bosserhoff AK, Vogt T, Buettner R, Bogenrieder T, Landthaler M, Stolz W. Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas. Melanoma Res 1998;8:504-9.
19. Zhang H, Schneider J, Rosdahl I. Expression of p16, p27, p53, p73 and Nup88 proteins in matched primary and metastatic melanoma cells. Int J Oncol 2002;21:43-8.
20. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. Possible oncogenic potential of DeltaNp73: a new isoform of human p73. Cancer Res 2002;62:636-41.
21. Vandenbroucke II, Vandesompele J, Paepe AD, Messiaen L. Quantification of splice variants using real-time PCR. Nucleic Acids Res 2001;29:E68-68.
22. Halaban R, Cheng E, Smicun Y, Germino J. Deregulated E2F transcriptional activity in autonomously growing melanoma cells. J Exp Med 2000;191:1005-16.
23. Chi SG, Chang SG, Lee SJ, Lee CH, Kim JI, Park JH. Elevated and biallelic expression of p73 is associated with progression of human bladder cancer. Cancer Res 1999;59:2791-3.
24. Sun XF. p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma. Clin Cancer Res 2002;8:165-70.
25. Korabiowska M, Ruschenburg I, Betke H, Stachura J, Schlott T, Cardo CC, Brinck U. Downregulation of the retinoblastoma gene expression in the progression of malignant melanoma. Pathobiology 2001;69:274-80.
26. Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, Nova P, Aglione S, Taillibert S, Khayat D. Metastatic melanoma: chemotherapy. Semin Oncol 2002;29:427-45.
27. Lassam NJ, From L, Kahn HJ. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 1993;53: 2235-8.
28. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E, Moll UM. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002;196:765-80.